Alpha Tau Medical (NASDAQ: DRTS) CFO sells 2,871 shares under 10b5-1 plan

Q: How many Alpha Tau Medical (DRTS) shares did the CFO sell in this filing?

The CFO reported selling 2,871 Ordinary Shares of Alpha Tau Medical Ltd. at a reported price of $15.0028 per share on August 21, 2026.

Q: Did the DRTS Form 4 show a net buy or net sell position for the CFO?

The transaction summary shows 2,871 shares sold and a net buy/sell direction of net-sell, reflecting the sale leg of the same-day exercise-and-sale sequence.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. (DRTS) reported that Chief Financial Officer Levy Raphi exercised derivative securities to acquire 2,871 Ordinary Shares at $2.98 per share on August 21, 2026, and on the same day sold 2,871 Ordinary Shares at $15.0028 per share pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

2 transactions reported

Mixed 2 txns

Insider Levy Raphi

Role Chief Financial Officer

Sold 2,871 shs ($43K)

Type	Security	Shares	Price	Value
Exercise	Ordinary Shares	2,871	$2.98	$9K
Sale	Ordinary Shares	2,871	$15.0028	$43K

Holdings After Transaction: Ordinary Shares — 90,180 shares (Direct)

Key Figures

Shares acquired: 2,871 Ordinary Shares Exercise price: $2.98 per share Shares sold: 2,871 Ordinary Shares +2 more

5 metrics

Shares acquired 2,871 Ordinary Shares Shares acquired via derivative exercise on August 21, 2026

Exercise price $2.98 per share Price for 2,871 Ordinary Shares acquired on August 21, 2026

Shares sold 2,871 Ordinary Shares Shares sold on August 21, 2026

Sale price $15.0028 per share Price for 2,871 Ordinary Shares sold on August 21, 2026

Net buy/sell shares -2,871 shares Transaction summary net buy/sell direction net-sell

Key Terms

Rule 10b5-1, Form 4, derivative securities, Ordinary Shares

4 terms

Rule 10b5-1 regulatory

"transactions were made pursuant to a Rule 10b5-1 trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Form 4 regulatory

"insider transactions did DRTS CFO Levy Raphi report on this Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

derivative securities financial

"reported exercising derivative securities to acquire 2,871 Ordinary Shares"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Ordinary Shares financial

"2,871 Ordinary Shares at $15.0028 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider transactions did DRTS CFO Levy Raphi report on this Form 4?

Levy Raphi reported exercising derivative securities to acquire 2,871 Ordinary Shares at $2.98 per share and selling 2,871 Ordinary Shares at $15.0028 per share on August 21, 2026.

Was the August 21, 2026 DRTS insider sale made under a Rule 10b5-1 plan?

Yes. The filing affirms the transactions were made pursuant to a Rule 10b5-1 trading plan, indicating they followed a pre-arranged trading schedule rather than discretionary timing.

How many Alpha Tau Medical (DRTS) shares did the CFO sell in this filing?

The CFO reported selling 2,871 Ordinary Shares of Alpha Tau Medical Ltd. at a reported price of $15.0028 per share on August 21, 2026.

What was the exercise price for the DRTS shares acquired by the CFO?

The shares acquired through the derivative exercise had a reported price of $2.98 per share for 2,871 Ordinary Shares on August 21, 2026.

Did the DRTS Form 4 show a net buy or net sell position for the CFO?

The transaction summary shows 2,871 shares sold and a net buy/sell direction of net-sell, reflecting the sale leg of the same-day exercise-and-sale sequence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/25/2026 - 10:35 AM Accepted by SEC EDGAR 08/25/2026 - 10:34 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Raphi

(Last)

(First)

(Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM

9777605

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/21/2026	08/21/2026	M		2,871	A	$2.98	93,051	D
Ordinary Shares	08/21/2026	08/21/2026	S		2,871	D	$15.0028	90,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	Raphi Levy	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR